... approved a label expansion for Novartis's Entresto, boosting its potential patient pool by millions of lives. The blockbuster drug is now approved for both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in patients whose left ventricular ejection fraction (LVEF) is below normal levels. For the treatment of chronic heart failure, Entresto currently holds preferred formulary placement for 50% of all covered lives, growing to 78% with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 2/17/21
No comments:
Post a Comment